When Pfizer offloaded gedatolisib to Celcuity in 2021, to many observers it looked like another failed…
Who's got the firepower in the SERD/PROTAC battle?
Highlights from various breast cancer trials and new pipeline developments
Who's going to be roaring forward?
An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer
How the SERD and PROTAC landscape might be shaking out
Segueing between preclinical and clinical data
Finding the right cell/right compartment isn't easy - it requires persistence and dedication
Hats off to companies pursuing an emerging target in breast cancer
A discussion of some of the key topics emerging in ER+ HER2- breast cancer
W2W4 on the TPD front
Review of some of the key trials in breast cancer being showcased in Paris next month
Key posters of interest at ESMO21
A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies
